GBM PAXALISIB ESMO 09/09/2022, page-2

This from a company 21 April, 2022 ASX release - obviously this is the final data presentation.

What is new in the data abstract, is this (from Dr Wen and Dr De Groot) -

---------------------------------------------------------------------------------------------------------

"At the MTD FDG-PET data provide evidence that paxalisib has the ability to exert biological effect in tumour tissue, irrespective of fed or fasted status "

----------------------------------------------------------------------------------------------------------
2104/2022

Patrick Wen, MD, Principal Investigator at Dana-Farber Cancer Institute, commented, “we look forward to presenting the final data from this phase II study and continuing our investigations in the multi-drug GBM AGILE study. Glioblastoma is a devastating diagnosis and we are encouraged by the prospect of providing new hope to this patient community”